ReNeuron Group Equity 2024

ReNeuron Group Aktienanalyse

What does ReNeuron Group do?

The ReNeuron Group PLC is a British biopharmaceutical company specializing in the development of novel therapies for the treatment of neurological diseases such as stroke, Parkinson's, and spinal cord injuries. It was founded in 1997 and is headquartered in Guildford, Surrey. ReNeuron initially focused on researching stem cells, particularly neural stem cells, to use them for the regeneration of nerve tissue. This innovative method was intended to revolutionize the treatment of brain and spinal cord injuries. In 2006, the company successfully developed and conducted clinical trials on the first neural stem cell therapy candidate. However, the development of cellular therapies posed challenges, particularly in terms of product safety and efficacy. Therefore, ReNeuron adjusted its business strategy and has since been working on the development of exosomal products and bioproducts. Exosomes are small membrane vesicles secreted by cells. The proteins, nucleic acids, and lipids contained within them play a crucial role in cellular processes and could represent a new class of therapeutic agents. With these two new focuses, ReNeuron aims to continue being innovative and maintain its position as a leader in the biotech industry. The ReNeuron Group PLC is divided into three main areas: Core Business, NeuDiscovery, and Incubator. The Core Business is dedicated to the development and commercialization of novel therapeutic approaches for neurological diseases. The company works on the development of exosomal products, bioproducts, and cell-based therapies to aid in brain and spinal cord injuries. In developing these products, the company collaborates closely with leading research institutions, universities, and other biopharma companies. In NeuDiscovery, ReNeuron follows an "Open-Platform" strategy and provides external researchers with access to its exosomal drug library. The company expects this to lead to the discovery of new therapeutic approaches and the application of its own technology in other areas of medicine. Incubator is an internal initiative aimed at creating and supporting start-up biotech companies. The company offers its technology and expertise to this division and invests in promising projects. ReNeuron has also brought several significant products to the market in the past, including an experimental drug for the treatment of strokes based on neural stem cells. This therapeutic program has the potential to be a groundbreaking approach in stroke treatment, reducing the need for long-term medical interventions such as rehabilitation. Overall, ReNeuron is a strong force in the biotech industry and has the potential to revolutionize the face of medicine. The company has proven its ability to develop innovative and effective therapies while also adapting its business strategy to meet the regulations of the biopharmaceutical environment. ReNeuron Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing ReNeuron Group's Equity

ReNeuron Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ReNeuron Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ReNeuron Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ReNeuron Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ReNeuron Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ReNeuron Group stock

What is the equity of ReNeuron Group this year?

ReNeuron Group has equity of 5.06 M GBP this year.

What was the equity of ReNeuron Group compared to the previous year?

The equity of ReNeuron Group has increased/decreased by -48.84% decreased compared to the previous year.

What impact does a high equity have on investors of ReNeuron Group?

A high equity is advantageous for investors of ReNeuron Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of ReNeuron Group?

A low equity can be a risk for investors of ReNeuron Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of ReNeuron Group affect the company?

An increase in equity of ReNeuron Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of ReNeuron Group affect the company?

A reduction in equity of ReNeuron Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of ReNeuron Group?

Some factors that can affect the equity of ReNeuron Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of ReNeuron Group so important for investors?

The equity of ReNeuron Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can ReNeuron Group take to change the equity?

To change equity, ReNeuron Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does ReNeuron Group pay?

Over the past 12 months, ReNeuron Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReNeuron Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of ReNeuron Group?

The current dividend yield of ReNeuron Group is .

When does ReNeuron Group pay dividends?

ReNeuron Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReNeuron Group?

ReNeuron Group paid dividends every year for the past 0 years.

What is the dividend of ReNeuron Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReNeuron Group located?

ReNeuron Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReNeuron Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReNeuron Group from 10/6/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did ReNeuron Group pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of ReNeuron Group in the year 2023?

In the year 2023, ReNeuron Group distributed 0 GBP as dividends.

In which currency does ReNeuron Group pay out the dividend?

The dividends of ReNeuron Group are distributed in GBP.